APASL clinical practice guidelines on the management of chronic hepatitis b infection: A 2026 update

Basit Öğe Kaydı
dc.authorid0000-0003-0110-5982
dc.authorid0000-0001-8827-3625
dc.authorid0000-0002-6613-0276
dc.authorid0000-0002-8618-6402
dc.authorid0000-0002-8909-2102
dc.contributor.authorYou, Hong
dc.contributor.authorMaiwall, Rakhi
dc.contributor.authorChen, Jing
dc.contributor.authorAhn, Sang Hoon
dc.contributor.authorDökmeci, Abdul Kadir
dc.contributor.authorDou, Xiaoguang
dc.contributor.authorEl-Sayed, Manal
dc.contributor.authorFan, Jian-Gao
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorGao, Zhiliang
dc.date.accessioned2026-03-17T11:29:12Z
dc.date.available2026-03-17T11:29:12Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractGlobally, especially in the Asia-Pacific region, chronic hepatitis B infection has led to an undesirable escalating morbidity and mortality with acute-on chronic liver failure, end-staged liver cirrhosis and hepatocellular carcinoma. This has happened despite the past four-decades of major scientific advances made in screening methods, vaccination strategies, highly effective low-cost anti-viral therapies and surveillance strategies for early detection of hepatocellular carcinoma. To address this health threat, APASL has formed a Viral Elimination Taskforce to unite key opinion leaders from its member countries and regions. The ongoing shifts in hepatitis B epidemiology, socioeconomic changes, and advancements in technology are taken into consideration. With the conjoint efforts of all the members of the APASL Viral Elimination Taskforce, this clinical practice guidelines have been formulated aiming to facilitate healthcare professionals, policy makers and patients in making practical and cost-effective management decisions for chronic hepatitis B infection. Altogether, it provides recommendations in thirteen major areas related to screening, vaccination, treatment and HCC surveillance. The implementation of this clinical practice guidelines represents major APASL effort toward elimination of the disease burden due to chronic hepatitis B infection in Asia-Pacific region.
dc.identifier.citationYou, H., Maiwall, R., Chen, J., Ahn, S. H., Dökmeci, A. K., Dou, X., El-Sayed, M., Fan, J. Ga., Örmeci, N., & Gao, Z. (2026). APASL clinical practice guidelines on the management of chronic hepatitis b infection: A 2026 update. pp. 1-64.
dc.identifier.endpage64
dc.identifier.startpage1
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1365
dc.institutionauthorÖrmeci, Necati
dc.institutionauthorid0000-0002-8909-2102
dc.language.isoen
dc.publisherAsian Pacific Association for the Study of the Liver (APASL)
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectChronic Hepatitis B
dc.subjectPrevention
dc.subjectTreatment
dc.subjectHepatocellular Carcinoma
dc.subjectTreat All
dc.subjectGuideline
dc.titleAPASL clinical practice guidelines on the management of chronic hepatitis b infection: A 2026 update
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
Tam Metin / Full Text.pdf
Boyut:
581.92 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu